Cross-Organ Differences Between IL-4Rα Blockade and IL-13-Selective Therapy in Immune-Priming and Barrier-Effector Compartments: Implications for Skin, Airway, and Gastrointestinal Diseases
Antibody therapies targeting the IL-4/IL-13 axis are used in type 2 inflammatory diseases affecting skin, airways, and gastrointestinal tissues. Clinical responses and biomarker behavior differ across organs, complicating trial interpretation and endpoint selection. We propose an IL-4Rα-centered framework that relates these differences to receptor-responsive cells, local cytokine supply, and the compartments sampled by each endpoint. Type I receptors (IL-4Rα/γc) support IL-4-dependent immune priming, including type 2 helper T-cell (Th2) differentiation and immunoglobulin E (IgE) class switching. Type II receptors (IL-4Rα/IL-13Rα1) respond to both IL-4 and IL-13 and are prominent in epithelial and mesenchymal effector programs. Selected immune populations also respond through Type II receptors. We connect receptor biology to organ-specific experimental mechanisms and clinical outcomes, distinguish within-cell receptor expression from tissue cellular composition, and consider IL-13Rα2 as a separate ligand-buffering regulator. These assignments are predominant tendencies rather than exclusive cellular localizations or validated treatment-selection rules. This approach links molecular, tissue, and clinical endpoints while avoiding claims of drug superiority based on cross-trial comparisons.
Authors
- Ryosuke Tanino (ORCID: https://orcid.org/0000-0002-5148-9526)
- Takayoshi Komatsu‐Fujii (ORCID: https://orcid.org/0000-0002-3085-6956)
Institutions
- Shimane University (JP)
- Kyoto University (JP)
Publication Details
- Journal
- Receptors
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3390/receptors5040036
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00